613 related articles for article (PubMed ID: 32936531)
21. Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.
Suganya S; Divya S; Parani M
Rev Med Virol; 2021 May; 31(3):e2174. PubMed ID: 32965078
[TBL] [Abstract][Full Text] [Related]
22. Variants in ACE2; potential influences on virus infection and COVID-19 severity.
Bakhshandeh B; Sorboni SG; Javanmard AR; Mottaghi SS; Mehrabi MR; Sorouri F; Abbasi A; Jahanafrooz Z
Infect Genet Evol; 2021 Jun; 90():104773. PubMed ID: 33607284
[TBL] [Abstract][Full Text] [Related]
23. Differential expression and immune correlation analysis of COVID-19 receptor ACE2 and TMPRSS2 genes in all normal and tumor tissues.
Hu RW; Liu C; Gong JP; Cao ZX
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1724-1731. PubMed ID: 33629341
[TBL] [Abstract][Full Text] [Related]
24. The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression.
Pivniouk V; Pivniouk O; DeVries A; Uhrlaub JL; Michael A; Pivniouk D; VanLinden SR; Conway MY; Hahn S; Malone SP; Ezeh P; Churko JM; Anderson D; Kraft M; Nikolich-Zugich J; Vercelli D
J Allergy Clin Immunol; 2022 Mar; 149(3):923-933.e6. PubMed ID: 34902435
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
Azar MM; Shin JJ; Kang I; Landry M
Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
[TBL] [Abstract][Full Text] [Related]
26. Genomic, epigenomic, and immune subtype analysis of CTSL/B and SARS-CoV-2 receptor ACE2 in pan-cancer.
Li H; Xie L; Chen L; Zhang L; Han Y; Yan Z; Guo X
Aging (Albany NY); 2020 Nov; 12(22):22370-22389. PubMed ID: 33231569
[TBL] [Abstract][Full Text] [Related]
27. Expression of SARS-CoV-2 Host Cell Entry Factors in Immune System Components of Healthy Individuals and Its Relevance for COVID-19 Immunopathology.
Kumar A; Kumar S; Narayan RK; Kumari C; Pareek V; Prasoon P
Viral Immunol; 2021 Jun; 34(5):352-357. PubMed ID: 33481684
[TBL] [Abstract][Full Text] [Related]
28. The contrasting role of nasopharyngeal angiotensin converting enzyme 2 (ACE2) transcription in SARS-CoV-2 infection: A cross-sectional study of people tested for COVID-19 in British Columbia, Canada.
Nikiforuk AM; Kuchinski KS; Twa DDW; Lukac CD; Sbihi H; Basham CA; Steidl C; Prystajecky NA; Jassem AN; Krajden M; Patrick DM; Sekirov I
EBioMedicine; 2021 Apr; 66():103316. PubMed ID: 33819740
[TBL] [Abstract][Full Text] [Related]
29. Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway.
Afshari A; Janfeshan S; Yaghobi R; Roozbeh J; Azarpira N
Infect Genet Evol; 2021 Mar; 88():104669. PubMed ID: 33301988
[TBL] [Abstract][Full Text] [Related]
30. Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms.
Aksoyalp ZŞ; Nemutlu-Samur D
Eur J Pharmacol; 2021 Dec; 912():174548. PubMed ID: 34606834
[TBL] [Abstract][Full Text] [Related]
31. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
32. Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions.
Abdelmoaty MM; Yeapuri P; Machhi J; Olson KE; Shahjin F; Kumar V; Zhou Y; Liang J; Pandey K; Acharya A; Byrareddy SN; Mosley RL; Gendelman HE
Front Immunol; 2021; 12():741502. PubMed ID: 34671355
[TBL] [Abstract][Full Text] [Related]
33. Immunopathogenesis and immunobiology of SARS-CoV-2.
Rabaan AA; Al-Ahmed SH; Al Mutair A; Alhumaid S; Sule AA; Tirupathi R; Fawzy M; Muhammad J; Khan A; Hasan A; Shrestha DB; Sah R; Dhawan M; Tiwari R; Bilal M; Ahmad T; Dhama K
Infez Med; 2021 Jun; 29(2):167-180. PubMed ID: 34061781
[TBL] [Abstract][Full Text] [Related]
34. An Impaired Inflammatory and Innate Immune Response in COVID-19.
Park SH
Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
[TBL] [Abstract][Full Text] [Related]
35. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.
Bouayad A
Rev Med Virol; 2020 Nov; 30(6):1-9. PubMed ID: 32734714
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 activates lung epithelial cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients.
Chen H; Liu W; Wang Y; Liu D; Zhao L; Yu J
EBioMedicine; 2021 Aug; 70():103500. PubMed ID: 34311326
[TBL] [Abstract][Full Text] [Related]
37. Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry.
Ragia G; Manolopoulos VG
Pharmacogenomics; 2020 Dec; 21(18):1311-1329. PubMed ID: 33243086
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
39. A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host.
Minakshi R; Jan AT; Rahman S; Kim J
Front Cell Infect Microbiol; 2020; 10():575404. PubMed ID: 33262955
[TBL] [Abstract][Full Text] [Related]
40. Is highly expressed ACE 2 in pregnant women "a curse" in times of COVID-19 pandemic?
Dhaundiyal A; Kumari P; Jawalekar SS; Chauhan G; Kalra S; Navik U
Life Sci; 2021 Jan; 264():118676. PubMed ID: 33129880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
